Illumina, Inc.

Tweet this page
<
2016
2017
2018
2019
2020
2021
2022
2023
>
Registration as it was on 16 Oct 2023
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

300,000€ - 399,999€

Financial year: Jan 2022 - Dec 2022

Lobbyists (Full time equivalent)

1.85 Fte (3)

Lobbyists with EP accreditation

2

High-level Commission meetings

7

Lobbying Costs over the years

  • Info

    Illumina, Inc.

    EU Transparency Register

    547949121038-83 First registered on 11 Mar 2016

    Goals / Remit

    Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

    Main EU files targeted

    Illumina follows policy and legislative developments related to genomics, agri-genomics, public health, animal health, agriculture, forensics, biotechnology, data protection, science, and research policies.

    In particular, Illumina follows the discussions on the proposal for a EU Health Data Space (EHDS) and developments relating to the Regulations on medical devices (MDR) and In-vitro diagnostics (IVDR). It also engages in policy and regulatory initiatives relating to research and innovation in the EU (Horizon Europe), including more generally developments relating to EU research programs, with a focus on genomics research.

    Additionally, Illumina focuses on policy developments related to the Beating Cancer Plan, the 1+Million Genomes Initiative, the EU Action on Antimicrobial Resistance (AMR), the EU Covid-19 policy response, the implementation of the NextGenerationEU Plan, and the EU orphan medicines legislation.

    Moreover, an emphasis is also given to monitoring the review in scope and responsibilities of key institutional stakeholders such as the European Medicine Agency (EMA), the European Center for Disease Control (ECDC) and the European Health Emergency preparedness and Response Authority (HERA).

    Address

    Head Office
    5200 Illumina Way
    San Diego null - CA 92122
    UNITED STATES
    EU Office
    Rue d'Arlon, 25 Topos - Illumina Inc.
    Brussels 1050 - Illumina
    BELGIUM

    Website

  • People

    Total lobbyists declared

    3

    Employment timeLobbyists
    100%1
    75%1
    10%1

    Lobbyists (Full time equivalent)

    1.85

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    2 accreditations were / are live (in bold) for the selected state of 18 May 2024

    Name Start date End Date
    Marie Helene FANDEL 18 Oct 2023 17 Oct 2024
    Federico PISANI 17 Aug 2023 16 Aug 2024
    Mr Jan NEUTZE 17 Dec 2022 16 Dec 2023
    Federico PISANI 31 Aug 2022 17 Aug 2023
    Miriam GARGESI 09 Aug 2022 05 Aug 2023
    Miriam GARGESI 10 Oct 2018 10 Oct 2019

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    MedTech Europe https://www.medtecheurope.org/

    Eucope https://www.eucope.org/

    All.Can https://www.all-can.org/

    European Cancer Organisation https://www.europeancancer.org/

    American Chamber of Commerce to the EU https://www.amchameu.eu/

    American European Community Association (AECA) https://aeca.org/

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2022 - Dec 2022

    Lobbying costs for closed financial year

    300,000€ - 399,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    None declared

    Intermediaries for current year

    None declared

    Closed year Costs

    300,000€ - 399,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Communication activities

    None

    Other activities

    None declared

  • Meetings

    Meetings

    7 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

    • Date 03 Dec 2021 Location Brussels
      Subject Presentation of the merger case Illumina and Grail
      Cabinet Cabinet of Commissioner Elisa Ferreira
      Portfolio Cohesion and Reforms
      Attending
      • Carole Mancel-Blanchard (Cabinet member)
    • Date 03 Dec 2021 Location Brussels, Belgium
      Subject The public health benefits and competition issues arising out of the merger between Illumina and GRAIL
      Cabinet Cabinet of Commissioner Janusz Wojciechowski
      Portfolio Agriculture
      Attending
      • Joanna Stawowy (Cabinet member)
    • Date 03 Dec 2021 Location Video-conference
      Subject Presentation of an early screening test by a cancer screening start-up. Its impact on health, early detection of cancer and especially on most vulnerable groups was discussed in the context of equality policy and the EU Beating Cancer strategy
      Cabinet Cabinet of Commissioner Helena Dalli
      Portfolio Equality
      Attending
      • Eva Gerhards (Cabinet member)
    • Date 03 Dec 2021 Location Brussels
      Subject Healthcare benefits of Cancer test
      Cabinet Cabinet of Vice-President Margaritis Schinas
      Portfolio Promoting the European Way of Life
      Attending
      • Chris Uregian (Cabinet member)
    • Date 03 Dec 2021 Location Virtual
      Subject Cancer Screening tests, Illumina-GRAIL Merger
      Cabinet Cabinet of Commissioner Mairead Mcguinness
      Portfolio Financial services, financial stability and Capital Markets Union
      Attending
      • Katherine Power (Cabinet member)
    • Date 12 Nov 2021 Location Videconference
      Subject Challenges of the health industrial ecosystem
      Cabinet Cabinet of Commissioner Thierry Breton
      Portfolio Internal Market
      Attending
      • Maurits-Jan Prinz (Cabinet member)
    • Date 29 Sep 2021 Location Brussels (virtual)
      Subject Illumina/GRAIL transaction, which in addition to important competition policy questions
      Cabinet Cabinet of President Ursula von der Leyen
      Portfolio President
      Attending
      • Anthony Whelan (Cabinet member)
      Other Lobbyists
Download this datacard